Home

Pharma China Web Edition

Pharma China Archives

Online Databases

Subscription/Order/Info

Event Calendar

China Pharma Providers

About Us

	News     The Market     Industry News     Regulatory News     General Health     Legal/IPR News     Product/R&D News     API/Bulk Drug News     People in the News     Other News     Top News Worldwide Feature articles     Editorials     Commentaries     Expert Opinions     Interviews     Case Studies     Company Profiles     Editor´s Picks Full Text Title

The Market Industry News Regulatory News General Health Legal/IPR News Product/R&D News API/Bulk Drug News People in the News Other News Top News Worldwide Editorials Commentaries Expert Opinions Interviews Case Studies Company Profiles Editor´s Picks

China to Face Repercussions of Irrational Cost Cutting as It Gets Ready to Revis... Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on the gloomy aftermath of irrational cost containment, late... (5/1/2019) Jack Ma Is Selling Cancer Coverage for Pennies a Month in China (5/21/2019) Diabetes Crisis Draws Challengers for $22 Billion Insulin Market (5/21/2019) FDA Defends Oversight Amid Questions of Safety of Generic Drugs Made in India and China (5/21/2019) Trade War With China Threatens To Make Problems With Generic Medicine Worse (5/21/2019) Chinese Tourists to Japan Switch from Shopping Sprees to Medical Services (5/17/2019) China Proposes Major Changes to Pharmaceutical Regulations (5/17/2019) One Min to Understand the Changes in the New Chinese Anti-Competition Law (5/16/2019) Developing Opportunities In Chinese Diabetes Market (5/16/2019) China Cashes In on the Cannabis Boom (5/9/2019) Chinese Bioethicists Call for 'Reboot' of Biomedical Regulation after Country's Gene-Edited Baby Scandal (5/9/2019) Progressive Reforms Shifting the Cancer Medicine Landscape in China (5/9/2019) China's Conditional Approval of Bayer's Acquisition of Monsanto: Lessons for Future Merger Cases in China (5/6/2019) Chinese Hospitals Set to Sell Experimental Cell Therapies (5/3/2019) Kangmei's $4bn Accounting Error Highlights China Risk (5/3/2019) (free) China to Face Repercussions of Irrational Cost Cutting as It Gets Ready to Revise the NRDL (5/1/2019) WuXi STA and Dizal Pharma Sign CMC Devel...  (5/21/2019) WuXi Biologics Signed Letter of Intent f...  (5/21/2019) Sandoz's Generic Rosuvastatin Cleared in...  (5/21/2019) Mabpharm Announces Proposed Listing on H...  (5/21/2019) European Chamber Report Calls for Urgent...  (5/21/2019) Premier Li Urges More Efforts to Advance...  (5/20/2019) China Raises Tariffs on U.S. MedPharm Pr...  (5/20/2019) Recent Executive Moves  (5/17/2019) NMPA Seeks Comments on Three Draft Docum...  (5/17/2019) China Approves Pfizer's Anticancer VIZIM...  (5/17/2019) Chinese Government Raised Healthcare Fun...  (5/17/2019) Zai Lab Files CTA for Phase 3 Trial of N...  (5/17/2019) Performance Overview of A Share-Listed C...  (5/16/2019) Performance of Top 15 Listed Chinese Dru...  (5/16/2019) A Birds-Eye-View of the Diabetes Drug Ma...  (5/16/2019) PhRMA Calls for Trade Deals That Force Countries to Pay ... IQVIA: Global Pharma to Grow Slower in the Next Five Yea... Pfizer and GSK Announce JV to Create a Global Consumer H... Top 25 Global Pharmaceutical Companies by Market Cap 201... CANbridge Receives IND Approval to Commence CAN008 Phase... A Birds-Eye-View of the Diabetes Drug Market of Major Provincia... New Report: As Star mAb Drug Patents Expire, Generic Drugs will... IQVIA Report Provides A Brids-Eye-View of Chinese Drug Market f... SMEI: Fastest Growing Products in the Top 200 Drugs by Sales Va... NH's DB6: Chinese OTC Drug Market Forecast 2018-2023 WuXi STA and Dizal Pharma Sign CMC Development and Manufactu... WuXi Biologics Signed Letter of Intent for Long-Term Vaccine... Sandoz's Generic Rosuvastatin Cleared in China Mabpharm Announces Proposed Listing on Hong Kong Stock Excha... China Raises Tariffs on U.S. MedPharm Products to 25% as Par... NMPA Seeks Comments on Three Draft Documents on Drug/Vac... NMPA Deepens Regulatory Harmonization with Hong Kong and... Latest Draft of Drug Administration Law Proposes to Ban ... NMPA Issues 2018 Food and Drug Regulatory Statistics Ann... CDE Publicizes Four More Drug Applications To Be Granted... European Chamber Report Calls for Urgent China Reforms amid ... NPC Solicits Public Comments on Amendment of the Drug Admini... NPC Solicits Public Comments on Amendment of the Vaccine Man... Bloomberg: U.S. Considers Drug Protection Concession in Chin... CNIPA Releases Draft Amendments to the Guidelines for Patent... China Issues Draft Positive List of Antibacterial Active... Chinese API Industry's Environmental Shake-up Disrupts V... U.S. Senators Propose Bill to Sanction Chinese Pharmchem... Lonza's Specialty API Business Disrupted by Chinese Plan... Huahai Pharma Involved In Another Blood Pressure Drug Re... Zai Lab Files CTA for Phase 3 Trial of Novel Anti-infect... Peritech Pharma Granted Drug Delivery Patents for China ... Innovent-Lilly Partnership Announces Positive Clinical R... NMPA Approves Sinovant's Clinical Trial Application for ... Hua Medicine Initiates First Combination Study of Dorzag... Premier Li Urges More Efforts to Advance Healthcare Refo... Chinese Government Raised Healthcare Funding by CNY 84B ... NHC Requires Enhanced Reporting of Hospital Statistical ... China Issues New Policy Document to Launch Trial for Dev... China to Raise Reimbursement Ratio of Critical Illness P... Recent Executive Moves Recent Executive Moves China Investigates Several Senior Local Drug Regulators fo... Chinese Pharma Billionaire Paid $6.5M to Get Daughter into... Pre-profit BeiGene Produced Two of the World's Highest Pai... Recent Chinese Study links Diabetes and Numerous Cancers... Auction - Pharma Site Closure in XiAn, China (Bid Due by... Upcoming Event: Pharma China Annual Forum 2019 (April 9,... Pharma China Annual Forum 2019 (April 9, Shanghai) Upcoming: Auction - Pharma Site Closure in XiAn, China (... Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector... WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...   WiCON to Hold Pharma China Ann...   WiCON Publishes the China Phar...   WiCON Officially Publishes Chi...   WiCON Officially Publishes Chi...   WiCON and PharmaGuys Launch Ph...

© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links